Active, not recruitingPhase 2NCT05345197
Emicizumab in Patients With Acquired Hemophilia A
Studying Acquired hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington
- Principal Investigator
- Rebecca Kruse-Jarres, MD, MPH, M.DUniversity of Washington
- Intervention
- emicizumab(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (16)
- UCSD Hemophilia and Thrombosis Treatment Center, San Diego, California, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- Emory University, Atlanta, Georgia, United States
- Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
- Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana, United States
- Tulane University, New Orleans, Louisiana, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Penn Blood Disorders Program, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
- University of Vermont Medical Center, Burlington, Vermont, United States
- UVA Comprehensive Cancer Center, Charlottesville, Virginia, United States
- Washington Center for Bleeding Disorders, Seattle, Washington, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05345197 on ClinicalTrials.govOther trials for Acquired hemophilia A
Additional recruiting or active studies for the same condition.